NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. SNNA, a clinical-stage biopharmaceutical company, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
|
||||||||||
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/328932f0-25cf-41f1-8753-d71506039e2e
http://www.globenewswire.com/NewsRoom/AttachmentNg/ec6059aa-d8d8-43f0-9b37-2c361dc69b24
Sienna Biopharmaceuticals, Inc. focuses on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Their objective is to develop their multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology patients. In comparison to many other segments of the biopharmaceutical industry, Sienna strives to make their product development and commercialization in dermatology and aesthetics relatively efficient in terms of time and cost.
"We are pleased to be listing on The Nasdaq Global Select Market as we complete our initial public offering," said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. "This is an important milestone for Sienna. We are dedicated to bringing patients topical innovations to improve outcomes through first-in-class products in dermatology and aesthetics."
"Sienna Biopharmaceuticals is one of the leaders in bringing innovations to the biotechnology industry. We are proud to have them join our family of disruptors, and look forward to witnessing their continued success as a public company," said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company's public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq
Nasdaq NDAQ is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com
- NDAQG -
Media Relations Contacts: Stephanie Lowenthal (646) 441-5073 Stephanie.Lowenthal@nasdaq.com Emily Pan (646) 441-5120 emily.pan@nasdaq.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
